Provided by Tiger Trade Technology Pte. Ltd.

Roundhill GLP-1 & Weight Loss ETF

29.93
-0.2559-0.85%
Post-market: 29.950.0121+0.04%19:30 EDT
Volume:9K
Turnover:279.68K
Market Cap:55.97M
PE:- -
High:30.22
Open:30.22
Low:29.84
Close:30.19
52wk High:37.15
52wk Low:27.34
Shares:1.87M
Float Shares:1.87M
Volume Ratio:0.84
T/O Rate:0.50%
Dividend:0.41
Dividend Rate:1.37%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Pfizer (PFE) Quietly Builds New Cancer And RSV Powerhouse

TIPRANKS
·
Yesterday

Viking Therapeutics Slides As Cash Raise Spooks Wall Street

TIPRANKS
·
Yesterday

Weight Loss Maintenance Data Could Be A Big Test For Viking Therapeutics Stock (VKTX)

Simply Wall St.
·
Yesterday

Pfizer (PFE) Receives a Hold from Leerink Partners

TIPRANKS
·
Yesterday

Eli Lilly & Co (LLY) Gets a Buy from RBC Capital

TIPRANKS
·
Yesterday

Novo Nordisk Says FDA Review of Hemophilia Drug is Hitting Delays

Dow Jones
·
Yesterday

NYSE Most Active Issues

Dow Jones
·
Yesterday

Former Eli Lilly Exec Sells Wyoming Estate for Close to $39.5 Million

Dow Jones
·
Yesterday

Eli Lilly announces FDA approves additional indication for Jaypirca

TIPRANKS
·
Yesterday

Lilly Says FDA Approves Expanded First-Line Cll/sll Use for Jaypirca

Reuters
·
Yesterday

Lilly's Jaypirca (Pirtobrutinib), the First-and-Only Approved Non-Covalent Btk Inhibitor, Receives Expanded Indication from U.S. FDA for Certain Patients with Previously Untreated Cll/Sll

THOMSON REUTERS
·
Yesterday

Pfizer Says Litfulo Safety Profile in NSV Consistent with Alopecia Areata

Reuters
·
Yesterday

Pfizer Tilrekimig Data Support TSLP Role in Atopic Dermatitis, UBS Says

MT Newswires Live
·
Yesterday

Novo Nordisk Tests Zenagamtide Dosing to Sharpen Its Obesity Drug Pipeline

TIPRANKS
·
Yesterday

Pfizer’s TACTIVE-U Breast Cancer Combo Trial Reaches Key Milestone

TIPRANKS
·
Yesterday

Novo Nordisk A/S Series B Stock Falls Friday, Underperforms Market

Dow Jones
·
Yesterday

Pfizer Says Phase 3 Trials Show Litfulo Improves Repigmentation in Nonsegmental Vitiligo Patients at Week 52

Reuters
·
Oct 02

Pfizer - to Submit Litfulo Phase 3 Data to FDA and Ema

THOMSON REUTERS
·
Oct 02

Pfizer - Litfulo Safety Profile in Nsv Consistent with Alopecia Areata; no New Safety Signals

THOMSON REUTERS
·
Oct 02

Pfizer’s Litfulo Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo~

THOMSON REUTERS
·
Oct 02